Clinical Trial Update: Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating panitumumab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. Results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-26